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Introduction: Rheumatoid arthritis (RA), a chronic inflammatory disease, is associated with insulin resistance.
Experimental evidence indicates that the relationship between insulin resistance and inflammation is bidirectional:
Inflammation promotes insulin resistance, and insulin resistance promotes inflammation. Therefore, we examined
the hypothesis that pioglitazone, a thiazolidinedione peroxisome proliferator-activated receptor γ agonist, would
decrease inflammation and disease activity and improve insulin resistance in patients with RA.
Methods: In a single-center, randomized, double-blind, placebo-controlled crossover study patients with RA
(N = 34) receiving stable therapy were randomized to also receive either pioglitazone 45 mg daily (n = 17) or
matching placebo (n = 17) for eight weeks. This was followed by a four-week washout period and alternative
treatment for eight weeks. Outcomes included change in Disease Activity Score in 28 joints (DAS28) score,
individual components of the DAS28 score and homeostatic model assessment for insulin resistance (HOMA).
Intention-to-treat analysis and linear mixed-effects models were used.
Results: Patients had a mean (±SD) age of 51 (±14.2) years, 82.4% were female and baseline DAS28 high-sensitivity
C-reactive protein (DAS28-CRP) was 4.58 (±1.1) units. Addition of pioglitazone was associated with a 9.3% reduction
(95% confidence interval (CI) = 0.17% to 17.6%) in DAS28-CRP (P = 0.046), but no significant change in DAS28
erythrocyte sedimentation rate (DAS28-ESR) (P = 0.92). There was a 10.7mm (95% CI = 0.4 to 20.9 mm) improvement
in patient-reported global health (P = 0.042), a 48.6% decrease (95% CI = 27.6% to 63.5%) in CRP
(P < 0.001) and a 26.4% decrease (95% CI = 3.7% to 43.8%) in insulin resistance as measured by HOMA (P = 0.025),
but no significant reduction in swollen or tender joint count or in ESR (all P > 0.05). Lower-extremity edema was
more common during pioglitazone treatment (16%) than placebo (0%).
Conclusion: Addition of pioglitazone to RA therapy improves insulin resistance and modestly reduces RA disease
activity measured by DAS28-CRP and two of its components, including patient-reported global health and CRP, but
not DAS28-ESR or ESR.
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Figure 1 Randomized, placebo-controlled, crossover trial
design. Patients were screened for eligibility. Those meeting entry
criteria were randomized to one of two treatment sequences:
pioglitazone then placebo or placebo then pioglitazone. Patients
were assessed every four weeks. Treatment phases were separated
by a four-week washout period.
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Patients with rheumatoid arthritis (RA), a chronic sys-
temic inflammatory disease, have an increased incidence
of premature atherosclerosis, even after adjusting for trad-
itional cardiovascular risk factors [1]. We have reported
previously that patients with RA have more than a twofold
increased incidence of insulin resistance and that this was
associated with inflammation, increased disease activity
and coronary atherosclerosis [2,3]. Moreover, insulin re-
sistance has been associated with increased inflammation
in populations without RA [4-8]. Additional evidence that
inflammation can promote insulin resistance is provided
by studies in animals and humans [9-11]. For example, in
diabetic rats, administration of tumor necrosis factor α
(TNF-α) caused hyperglycemia [12], and, in obese rats,
neutralization of TNF-α improved insulin resistance [13].
In humans, treatment of active RA, even with corticoste-
roids, a class of drug which would be expected to increase
insulin resistance, can decrease insulin resistance, presum-
ably by decreasing inflammation [14].
Recent evidence indicates that, just as inflammation
may result in insulin resistance, hyperinsulinemia may
increase inflammation. For example, in vitro studies
have shown that glucose and insulin-like growth factors
augment the secretion of inflammatory cytokines in
mononuclear cells [15,16]. Also, in humans, euglycemic
hyperinsulinemia amplifies and prolongs the interleukin 6
(IL-6) response to endotoxin [17]. Thus, there appears to
be a bidirectional relationship between inflammation and
hyperinsulinemia.
Concordant with the finding that insulin resistance may
promote inflammation, therapies which improve insulin
resistance may decrease inflammation. Thiazolidinediones,
selective ligands of the nuclear transcription factor peroxi-
some proliferator-activated receptor γ (PPAR-γ), are insu-
lin sensitizers, even in individuals without diabetes [18].
Studies in animals, including a model of arthritis, as well
as in patients with psoriatic arthritis and lupus, have
shown that, in addition to improving insulin sensitivity,
thiazolidinediones decrease inflammation [19-28].
We therefore performed this study to test the hypoth-
esis that pioglitazone would decrease disease activity, in-
flammation and insulin resistance in patients with RA.
Methods
Patients
Patients older than 18 years of age who met the 1987
American Rheumatism Association criteria for RA [29]
with moderate disease activity (at least three tender and
three swollen joints) and no change in immunomodulating
or anti-inflammatory therapy in the past one month were
eligible for enrollment. Patients were excluded if they had
active cancer other than skin cancer, HIV, heart failure, se-
vere edema, diabetes mellitus requiring drug therapy,aspartate aminotransferase or alanine aminotransferase
greater than twice the upper limit of normal, major surgery
within the previous three months, untreated osteoporosis,
allergy to pioglitazone, previous organ or bone marrow
transplant or severe comorbid conditions likely to com-
promise survival or study participation. Patients were also
excluded if they were receiving dialysis, taking gemfibrozil
or rifampin or unwilling or unable to cooperate. Addition-
ally, patients were excluded they were pregnant, or if they
had childbearing potential and would not agree to affective
birth control. After reviewing reports about the possible as-
sociation between pioglitazone and bladder cancer [30,31],
we excluded patients with a history of bladder cancer or
precancerous bladder lesions. The study was approved by
the Vanderbilt University Institutional Review Board, and
all participants gave their written informed consent.
Study design
This trial was a single-center, randomized, double-blind,
placebo-controlled crossover study with washout. We
chose to use a crossover study design because this model
increases the power to detect a difference with small
sample sizes by reducing between-patient variability and
the effect of confounders when each patient serves as
his or her own control. Patients were randomly assigned
to receive pioglitazone 45 mg or matching placebo daily
for eight weeks in combination with unchanged doses of
their baseline disease-modifying antirheumatic drug
(DMARD) therapy. This treatment was followed by a four-
week washout period, then a second eight-week treatment
period with the alternative therapy (Figure 1). Study visits
occurred at screening, at baseline (week 0) and every four
weeks through week 20 or withdrawal from the study. Pa-
tients were randomly assigned to a treatment sequence
(placebo or pioglitazone first) according to a randomization
table generated using a permuted block randomization
scheme prepared by the study statistician. Pioglitazone or
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University investigational pharmacy. If a change in RA
disease status warranted any change in DMARD or
corticosteroid therapy, the patient was withdrawn from the
study.
At the baseline (week 0) visit, the following clinical
details were obtained from the patient and the medical
records: height, weight, waist and hip measurements;
blood pressure; current and past smoking history; per-
sonal and family history of cardiovascular disease; medi-
cation use, including current and past DMARD use;
current and cumulative prednisone therapies; and car-
diovascular therapies.
At baseline and at each subsequent visit, participants
were asked to temporarily omit medications, including
nonsteroidal anti-inflammatory drugs (NSAIDs) and cor-
ticosteroids, on the morning of the study day. Patients
were studied after at least 6 hours of fasting and after 30
minutes of supine rest at approximately the same time
of day. A physical examination was performed, and RA
disease activity indices, including 28 tender and swollen
joint counts, were measured and venous blood was
drawn for laboratory assessments. Urine and/or serum
pregnancy tests were performed at each study visit in fe-
males with reproductive potential.
Laboratory examinations comprising a complete blood
count; creatinine, glucose and liver function tests (LFTs);
high-sensitivity C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR) were performed by the hospital
clinical laboratory staff. Fasting plasma insulin levels
were measured at the Vanderbilt Hormone Assay Core
Laboratory by radioimmunoassay. Serum cytokines, in-
cluding tumor necrosis factor α (TNF-α) and IL-6, were
measured by multiplex enzyme-linked immunosorbent
assay (EMD Millipore, Billerica, MA, USA) in duplicate
in batches with samples from each time point in a given
patient run together on the same plate with appropriate
controls and blocking agents. All measurements were
taken at the beginning and end of each treatment arm.
Outcome measures
The primary outcome was change in Disease Activity
Score in 28 joints (DAS28) score (calculated as DAS28-
CRP = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 *
ln(CRP) + 0.014 * global health (GH) and DAS28-ESR =
0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln
(ESR) + 0.014 * GH). Other prespecified outcomes in-
cluded individual components of the DAS28 score, includ-
ing tender and swollen joint count, patient-reported
GH based on 1- to 100-mm Visual Analogue Scale (VAS)
rating and acute-phase reactants (CRP, ESR); level of in-
flammatory cytokines IL-6 and TNF-α; change in func-
tional capacity determined using the modified Health
Assessment Questionnaire (MHAQ) [32]; and change ininsulin resistance determined by the homeostatic model
assessment for insulin resistance (HOMA), calculated as
(fasting glucose [in mmol/L] × fasting insulin [in μU/ml])/
22.5 [33].
Statistical analysis
Sample size was estimated using a paired t-test and as-
suming a baseline DAS28 score of 5.0 ± 1.0 units [34,35].
A sample size of 32 patients would provide 90% power
to detect a 0.6-unit greater decrease in DAS28 score in
patients taking pioglitazone compared to placebo after
excluding dropouts (defined as having no follow-up
study visits). We initially aimed to enroll 36 patients
with the assumptions that 4 patients would drop out
(defined as not returning for any visits) and 32 patients
would provide data for analysis. We stopped enroll-
ment after patient 34, however, because there had been
no dropouts.
Descriptive statistics are presented as frequencies and
percentages (%) for categorical variables and means with
standard deviations (mean ± SD) for continuous vari-
ables. Linear mixed-effects models were used to quantify
the effect of pioglitazone on outcomes. Data gathered
from all study visits from all patients, including those
who exited the study early and those who were with-
drawn, were used in the analysis. The linear mixed-
effects models were fitted for all outcomes separately.
These modeled the fixed effects of the baseline value of
the outcome, treatment regimen, week and product of
week and treatment regimen. Random intercepts were
used to model the variability between patients. For all
the primary and secondary outcomes, the carryover ef-
fect was assessed by comparing the means of the base-
line outcome measurements between patients who
received pioglitazone in the first phase followed by pla-
cebo and those who received placebo in the first phase
followed by pioglitazone using linear mixed-effects
models with random intercepts for between-patient vari-
ations. Because we used a two-arm crossover design in
this study, data were pooled between the two treatment
phases after finding no carryover effect, and we report
between-group differences at the end of study time
points (week 8 and week 20) using general contrast of
regression coefficients in the mixed-effects models.
To assess whether pioglitazone’s effect on HOMA medi-
ated the effect on disease indices such as DAS28-CRP, we
used mixed-effect models to examine attenuation in the
effect of the treatment by adjustment for the change in
HOMA [36]. The values for DAS28-CRP, DAS28-ESR,
CRP, ESR, MHAQ, IL-6, TNF-α and HOMA were all nat-
ural logarithm–transformed to improve normality in the
residuals. Thus, changes in these outcomes were back-
transformed and presented as percentage changes. Statis-
tical analyses were performed using the R Project for
Ormseth et al. Arthritis Research & Therapy 2013, 15:R110 Page 4 of 9
http://arthritis-research.com/content/15/5/R110Statistical Computing version 2.15.1 software (http://www.
r-project.org/). A two-sided significance level of 5% was
required to consider the data as statistically significant.
Results
Patients
The study was performed from May 2009 to April 2012.
Thirty-four patients with RA were studied (Figure 2).
Patients had a mean age (±SD) of 51.0 years (±14.2),
82.4% were female and the baseline mean DAS28-CRP
was 4.58 units (±1.1). Of the 28 patients with available
rheumatoid factor (RF) or anti-citrullinated peptide anti-
body (ACPA) test results, 24 (85.7%) were RF- or ACPA-
positive. Of the 21 patients with X-rays, 15 (71.4%) had
erosive disease. The baseline characteristics of the pa-
tients are shown in Table 1.
Effect of pioglitazone on rheumatoid arthritis disease
indices and inflammatory markers
The addition of pioglitazone was associated with a 9.3%
decrease (95% confidence interval (95% CI) = 0.17% to
17.6%) in DAS28-CRP (P = 0.046) compared to placebo;Figure 2 Randomization and follow-up of study participants. A total o
There was at least one follow-up visit for all patients. A total of 31 patients
liver function test.however, the effect of pioglitazone on DAS28-ESR
was not statistically significant (P = 0.92) (Table 2 and
Figure 3). Individual components of the DAS28 score
were evaluated. Pioglitazone was associated with a
10.7-mm improvement (95% CI = 0.4- to 20.9-mm) in
patient-reported GH on the VAS (P = 0.042) and a 48.6%
decrease in CRP (95% CI = 27.6% to 63.5%) (P < 0.001),
but no significant change in swollen joint count (P = 0.77),
tender joint count (P = 0.54) or ESR (P = 0.32) compared
to placebo (Table 2). There was no significant change in
MHAQ score (P = 0.51) with pioglitazone use (Table 2).
Use of pioglitazone was associated with a 67.0% reduction
in IL-6 (95% CI = 28.2% to 84.6%) (P = 0.01), but no
significant change in TNF-α (P = 0.71) (Table 2).
Effect of pioglitazone on insulin resistance and
relationship to disease indices
Use of pioglitazone was associated with a 26.4% decrease
(95% CI = 3.7% to 43.8%) in insulin resistance as measured
by HOMA (P = 0.025) (Table 2). To determine whether
improvement in insulin resistance caused the improve-
ments in disease activity indices, we compared the resultsf 34 patients with rheumatoid arthritis (RA) were enrolled in the study.
were exposed to pioglitazone, and 32 were exposed to placebo. LFT,
Table 1 Baseline demographics and clinical characteristics
of patientsa
Demographics and characteristics Data
Demographics and anthropomorphic measures
Age (years) 51.0 (±14.2)
Females (%) 82.4% (28)
Race, Caucasians (%) 85.3% (29)
Weight (kg) 77.3 (±18.1)
BMI (kg/m2) 28.28 (±6.04)
Disease-related and laboratory indices
DAS28-CRP (units) 4.58 (±1.10)
Tender joints (n) 9.68 (±6.96)
Swollen joints (n) 8.38 (±4.66)
VAS (mm) 43.0 (±28.5)
CRP (mg/dl) 12.69 (±24.57)
ESR (mm/h) 22.8 (±21.3)
HOMA (units) 3.11 (±2.68)
Current medication use
Methotrexate (%) 70.6% (24)
Leflunomide (%) 14.7% (5)
Sulfasalazine (%) 2.9% (1)
Hydroxycholorquine (%) 17.6% (6)
Biologic (%) 52.9% (18)
Corticosteroid (%) 52.9% (18)
aData are presented as mean (±SD) for continuous data and percentage
(number) for categorical variables. BMI, body mass index; CRP, high-sensitivity
C-reactive protein; DAS28-CRP, Disease Activity Score in 28 joints high-
sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; HOMA,
homeostatic model assessment of insulin resistance; VAS, Visual Analogue
Scale for Global Health.
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itional adjustment for HOMA. There was no attenuation
of effect after adjustment for HOMA: DAS28-CRP, −9.8%
(95% CI = −18.1% to –0.6%; P = 0.037); CRP, −48.9%
(95% CI = −66.2 to −22.8%; P = 0.001); VAS, 10.5 mm
(95% CI = −19.6 to −1.35; P = 0.002); and IL-6, −71% (95%
CI = −87.8 to −31.8%; P = 0.005). Thus, we determined
that there was no statistical evidence that pioglitazone’s
effect on HOMA mediated changes in outcome measures
of inflammation.
Drug side effects
Treatment with pioglitazone was generally well-tolerated.
Adverse effects related to the drug included lower-
extremity edema in five patients (16%) compared to none
among those taking placebo. Four patients were with-
drawn during the pioglitazone arms of the study (one each
due to leukopenia, LFT elevation, new prednisone use and
lower-extremity edema). Similarly, four patients were
withdrawn during the placebo arms of the study (one eachdue to LFT elevation, RA flare, unintended pregnancy and
patient choice) (Figure 2). Use of pioglitazone was associ-
ated with a 0.76 kg increase (95% CI = 0.10 to 1.42 kg) in
body weight (P = 0.023).
Washout and assessment for carryover effect
There was no carryover effect detected for DAS28-CRP
(P = 0.92) or other outcomes evaluated (all P > 0.05).
Discussion
The major findings of this study are that the addition of
pioglitazone to stable DMARD treatment for RA im-
proves insulin resistance, as measured by HOMA, and
modestly reduces RA disease activity, as measured by
DAS28-CRP, patient-reported GH and CRP levels. The
reductions in DAS28-CRP, CRP and IL-6 levels were in-
dependent of improvement in insulin resistance.
Several lines of evidence support the idea that PPAR-γ
agonists have anti-inflammatory effects. PPAR-γ expres-
sion in peripheral monocytes and monocyte-derived
macrophages in RA patients was inversely correlated
with disease activity, and some medications commonly
used in the treatment of RA (methotrexate and cortico-
steroids) increase PPAR-γ expression [37]. In animal
models of RA, thiazolidinedione treatment reduced
synovitis, inflammatory bone loss and bone erosion
[23-25]. Moreover, a recent single-blind trial suggested
improvement in disease activity in diabetic patients with
active RA, but an adequate comparator control was not
used; thus, definitive conclusions regarding efficacy
could not be made [25]. Additionally, in an open-label
trial of patients with psoriatic arthritis, pioglitazone re-
duced both tender and swollen joint counts [26], and
pioglitazone decreased CRP and serum amyloid A and
improved insulin sensitivity in patients with uncompli-
cated systemic lupus erythematosus [27].
Our findings raise the possibility that pioglitazone
may have different effects on CRP compared to ESR.
CRP is produced in the liver in response to IL-6 [38],
whereas ESR is a laboratory phenomenon affected by fi-
brinogen, immunoglobulin levels and red blood cell
count and shape, among other factors [39,40]. Several
studies have found that pioglitazone decreased CRP con-
centrations [19-21], but ESR has not been measured
routinely in most clinical trials of pioglitazone or other
thiazolidinediones. However, in one study that included
nondiabetic patients with known cardiovascular disease,
pioglitazone resulted in a nonsignificant trend toward
increased ESR [41]. The decrease in IL-6 concentrations
we observed after pioglitazone therapy is mechanistically
concordant with the reduction in CRP that occurred,
but factors driving ESR may not have been altered as
much [42,43]. In contrast to IL-6, TNF-α concentrations
were not significantly affected by pioglitazone, raising
Table 2 Effect of pioglitazone on rheumatoid arthritis disease activity, inflammation and insulin resistancea
Measurement Pioglitazone phase Placebo phase Pioglitazone treatment effect
Baseline Week 8/week 20 Baseline Week 8/week 20 Effect P-value
(SD) (SD) (SD) (SD) (95% CI)
DAS28-CRP 4.40 4.03 4.57 4.48 −9.3% 0.046
(1.00) (1.15) (1.28) (1.20) (−17.6 to −0.17%)
DAS28-ESR 4.56 4.37 4.85 4.57 0.6% 0.92
(1.39) (1.28) (1.56) (1.63) (−10.3 to 12.7%)
Swollen joints (n) 6.6 6.46 8.2 7 0.3 0.77
(3.7) (4.79) (5.6) (5.11) (−1.4 to 1.9)
Tender joints (n) 9.6 8.54 11.5 10.35 −0.7 0.54
(6.89) (7.28) (8.1) (8.23) (−2.9 to 1.5)
VAS (mm) 44.9 42.04 48.0 49.46 −10.7 0.042
(24.7) (28.39) (31.2) (23.62) (−20.9 to −0.4)
CRP (mg/dl) 8.1 5.02 7.7 8.25 −48.6% <0.001
(11.41) (7.64) (13.6) (10.32) (−63.5 to −27.6%)
ESR (mm/h) 18.5 17 19.5 18.88 21.3% 0.32
(18.2) (17.06) (20) (20.80) (−16.9 to 77%)
IL-6 (pg/ml) 5.41 2.38 8.67 6.47 −67.0% 0.01
(7.88) (4.05) (19.31) (14.40) (−84.6 to −28.2%)
TNF-α (pg/ml) 9.90 9.50 13.40 9.71 6.0% 0.71
(10.64) (10.56) (19.41) (7.91) (−22.7 to 46.2%)
MHAQ (units) 0.55 0.54 0.56 0.59 −4.3% 0.51
(0.37) (0.39) (0.35) (0.36) (−16.2 to 9.3%)
HOMA (units) 2.83 2.44 2.38 3.11 −26.4% 0.025
(2.50) (2.08) (1.75) (3.47) (−43.8 to −3.7%)
aData for each intervention phase (pioglitazone and placebo) at baseline and at week 8/week 20 are presented as mean (±SD). Pioglitazone treatment effect was
calculated using linear mixed-effects models and is presented as change or percentage change (95% confidence interval). CRP, high-sensitivity C-reactive protein;
DAS28-CRP, Disease Activity Score in 28 joints high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; HOMA, homeostatic model assessment of
insulin resistance; IL-6, interleukin 6; MHAQ, modified Health Assessment Questionnaire; TNF-α, tumor necrosis factor α; VAS, Visual Analogue Scale for
Global Health.
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on IL-6 than on TNF-α. These modest effects of
pioglitazone suggest it is unlikely to be a helpful add-on
therapy for reduction of RA disease activity, particularly
when one considers the increased risk for fracture, blad-
der cancer and heart failure in some individuals [44-46].
As part of our analysis, we set out to define whether
changes in insulin sensitivity were related to changes in
inflammation because this would provide a mechanistic
insight. We found that improvements of DAS28-CRP,
CRP and IL-6 after pioglitazone treatment were inde-
pendent of improvements in HOMA, suggesting that
mechanisms other than improved insulin sensitivity are
likely to be involved. These findings are compatible
with those of a study of healthy participants showing
that rosiglitazone reduced CRP within one day, before
changes in insulin sensitivity had occurred [47]. Thus,
thiazolidinediones may affect inflammation rapidly,before the effects on insulin resistance have occurred,
through mechanisms independent of improved insulin
sensitivity [47-51].
Our study has some limitations. This study was rela-
tively small, but it was efficiently designed to study the
outcomes of interest. The crossover design has the
advantage of comparing changes in the same patient
and the disadvantage that subtle, undetected carryover
effects may have occurred. Several mean baseline disease
activity indices (DAS28-CRP, DAS28-ESR, swollen and
tender joint counts, VAS, IL-6 and TNF-α) were slightly
lower at the start of the pioglitazone phase compared
to the baseline of the placebo phase. Though not a sig-
nificant difference, lower disease activity in patients
entering the treatment phase could have biased our re-
sults toward the null hypothesis. Also, inflammatory
cytokine levels were relatively low even at baseline be-
cause patients were receiving fairly effective background







Figure 3 Rheumatoid arthritis disease activity measured by Disease Activity Score in 28 joints score is decreased by pioglitazone. The
graph on the left shows the change in Disease Activity Score in 28 joints high-sensitivity C-reactive protein (DAS28 CRP) scores among patients
randomized to receive pioglitazone first, then placebo. The graph on the right shows change in DAS28-CRP scores among patients randomized
to receive placebo first, then pioglitazone. Red designates patients taking pioglitazone, and black represents those taking placebo. Open circles
represent mean change, and bars represent 95% confidence intervals.
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null hypothesis. Duration of drug exposure was only
eight weeks, which is shorter than most trials of
DMARDs and biologics; therefore, we cannot exclude
the possibility that extended exposure to pioglitazone
may have had different effects on joint counts and over-
all disease activity.
Conclusion
Addition of pioglitazone to RA therapy improves
insulin resistance and modestly reduces RA disease
activity measured by DAS28-CRP and two of its
components, patient-reported GH and CRP, but not
DAS28-ESR or ESR.
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